Evidence map›Paper›PMID 38041933›Full record

ReviewCurrent opinion in pharmacology2023

Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.

Andrew J Shepherd, Andrew Sc Rice, Maree T Smith

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Andrew J ShepherdThe MD Anderson Pain Research Consortium and the Laboratories of Neuroimmunology, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew Sc RicePain Research, Department of Surgery & Cancer, Imperial College London, London, UK.
Maree T SmithSchool of Biomedical Sciences, The University of Queensland, St Lucia Campus, Brisbane, Queensland, Australia. Electronic address: maree.smith@uq.edu.au.
Imperial College London · GBThe University of Queensland · AUThe University of Texas MD Anderson Cancer Center · US

Funding

Non-addictive Angiotensin AT2 inhibitors for neuropathic pain reliefUH3NS116929 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEREZOV, VADIM, KATRITCH, VSEVOLOD · 2021 to 2023
$1.9M
Angiotensin Signaling Underlies Myeloid and Sensory Disruption in DiabetesR01DK132019 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Andrew John Shepherd · 2024 to 2026
$1.6M
NIDDK NIH HHS R01 DK132019NINDS NIH HHS UH3 NS116929
6 · The paper itself

Abstract

Translating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT

Indexed as

NeuralgiaReceptor, Angiotensin, Type 2Angiotensin II Type 2 Receptor BlockersBenzhydryl CompoundsHumansIsoquinolinesAngiotensin II Type 2 Receptor BlockersBenzhydryl CompoundsEMA400IsoquinolinesReceptor, Angiotensin, Type 2

Identifiers

PMID38041933
PMCPMC11789660
OpenAlexW4389235769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.